Musings from The Power List: Peng Lu

Peng Lu argues that small molecules remain indispensable as AI transforms drug development

1

Peng Lu highlighted the advancement of the late-stage clinical program for bradykinin-mediated angioedema over the past year.
2

The RAPIDe-3 study provided topline data suggesting that deucrictibant may offer a differentiated profile for treating hereditary angioedema attacks.
3

Peng Lu emphasized the importance of preparing for the submission of the New Drug Application for investigational deucrictibant.
4

Small molecules maintain advantages in oral bioavailability, manufacturing, and reduced immunogenicity compared to newer modalities.
5

The integration of translational science and AI is rapidly evolving, enhancing decision-making and study design in drug development.

1